Friday, June 27, 2025 1:07:32 PM
$PHRRF increasing nicely each of the last 8 trading days. Sweet!
Bullish
Recent PHRRF News
- PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery • Newsfile • 04/16/2026 12:00:00 PM
- PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology • Newsfile • 04/13/2026 12:00:00 PM
- PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches • Newsfile • 03/26/2026 12:00:00 PM
- PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market • Newsfile • 03/03/2026 01:00:00 PM
- PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success • Newsfile • 02/02/2026 02:27:00 PM
- PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs • Newsfile • 01/14/2026 01:00:00 PM
- PharmaTher CEO Publishes Letter to Shareholders • Newsfile • 01/02/2026 01:00:00 PM
- PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise • Newsfile • 12/02/2025 02:53:00 PM
- PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program • Newsfile • 11/17/2025 01:00:00 PM
- PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale • Newsfile • 10/17/2025 12:26:00 PM
- PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease • Newsfile • 10/16/2025 12:00:00 PM
- PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings • Newsfile • 10/15/2025 12:00:00 PM
- PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease • Newsfile • 10/08/2025 12:00:00 PM
- PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy • GlobeNewswire Inc. • 10/02/2025 12:00:00 PM
- PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments • Newsfile • 10/01/2025 12:00:00 PM
- PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments • GlobeNewswire Inc. • 10/01/2025 12:00:00 PM
- Psychedelic Pharma Stock Surges on FDA Breakthrough • AllPennyStocks.com • 08/11/2025 07:30:00 PM
